AIDSmeds founder Peter Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England, about new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke.

Study Finds Viread Advantages in Black Patients

Twice-Daily Kaletra Possibly Better for Some Patients

Once-Daily Viramune Strikes Out

Fewer Side Effects with Videx/Epivir vs. Combivir

Still No Clear Benefit of Treating Early HIV (Reuters Health)

One in 10 Infected with Drug-Resistant HIV

Non-Nuke TMC-278 Comparable to Sustiva

Integrase Inhibitor Elvitegravir (GS-9137) Shows Well

Isentress (MK-0518) Results Prove Promising

Encouraging Data from Two Maraviroc Studies

Baraclude Induces HIV Drug Resistance

HIV+ Less Responsive to Lipid-Lowering Meds

Study Says Less Fat for Lower Lipids

Shift in Cancer-Related Deaths in HIV

TH9507 Shows Promise for Lipodystrophy

More Lipoatrophy with Sustiva vs. Kaletra

Zetia Lowers 'Bad' LDL Cholesterol

Fosamax, Calcium, and Vitamin D for Bone Weakness

Breastfeeding Safer for Some HIV+ Mothers (Reuters Health)

The Plot Thickens: HIV Treatment Challenges

The Skinny on Metabolic Complications

What's New? Update on Experimental Agents

Diary of a Doc: On the Origins of HIV

Diary of a Doc: New Strategies for HIV-Herpes Coinfection